TrialCancer medicine2017

A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status.

Benjamin Izar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.